Jeffrey T Summers, MD | |
2470 Flowood Drive, Flowood, MS 39232 | |
(877) 554-4257 | |
(601) 983-2845 |
Full Name | Jeffrey T Summers |
---|---|
Gender | Male |
Speciality | Pain Management |
Experience | 41 Years |
Location | 2470 Flowood Drive, Flowood, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336257500 | NPI | - | NPPES |
050081213 | Other | MS | RAILROAD MEDICARE |
00113488 | Medicaid | MS |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Newsouth Neurospine, Llc | 2163591579 | 21 |
News Archive
ConvaTec, a world-leading developer of innovative medical technologies for community and hospital care, today presented data supporting the safety and efficacy of Vitala™, a novel, non-intrusive pouchless ostomy device that provides temporary continence to people with a colostomy. The clinical trial data were presented at the 2010 Joint Conference of the Wound, Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET), where the new device is being previewed to U.S. and global healthcare professionals.
Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.
Analysts predict the poverty rate will decline by up to half a percentage point from its current level of 15 percent, or 46.2 million people.
Adults are more compassionate and are up to twice as likely to donate to charity when children are present, according to a new study from psychologists.
› Verified 3 days ago
Entity Name | Newsouth Neurospine, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326222548 PECOS PAC ID: 2163591579 Enrollment ID: O20080527000108 |
News Archive
ConvaTec, a world-leading developer of innovative medical technologies for community and hospital care, today presented data supporting the safety and efficacy of Vitala™, a novel, non-intrusive pouchless ostomy device that provides temporary continence to people with a colostomy. The clinical trial data were presented at the 2010 Joint Conference of the Wound, Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET), where the new device is being previewed to U.S. and global healthcare professionals.
Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.
Analysts predict the poverty rate will decline by up to half a percentage point from its current level of 15 percent, or 46.2 million people.
Adults are more compassionate and are up to twice as likely to donate to charity when children are present, according to a new study from psychologists.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Jeffrey T Summers, MD 2470 Flowood Drive, Flowood, MS 39232 Ph: (877) 554-4257 | Jeffrey T Summers, MD 2470 Flowood Drive, Flowood, MS 39232 Ph: (877) 554-4257 |
News Archive
ConvaTec, a world-leading developer of innovative medical technologies for community and hospital care, today presented data supporting the safety and efficacy of Vitala™, a novel, non-intrusive pouchless ostomy device that provides temporary continence to people with a colostomy. The clinical trial data were presented at the 2010 Joint Conference of the Wound, Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET), where the new device is being previewed to U.S. and global healthcare professionals.
Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.
Analysts predict the poverty rate will decline by up to half a percentage point from its current level of 15 percent, or 46.2 million people.
Adults are more compassionate and are up to twice as likely to donate to charity when children are present, according to a new study from psychologists.
› Verified 3 days ago